DCM Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

DCM Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-795	Closed	-$472K	–	211
2022 Q2	$472K	Buy	+795	New	+$517K	0.2%	113
2021 Q4	–	Sell	-425	Closed	-$257K	–	303
2021 Q3	$257K	Hold	425	–	–	0.1%	207
2021 Q2	$237K	Buy	+425	New	+$215K	0.13%	174
2021 Q1	–	Sell	-880	Closed	-$425K	–	272
2020 Q4	$425K	Buy	+880	New	+$475K	0.25%	111

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DCM Advisors's REGN Position: Q3 2022 in Review

DCM Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 795 shares — an estimated $472K sold.

DCM Advisors first reported a position in REGN in Q4 2020 and held it in 4 quarters. The position peaked at $472K in Q2 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

DCM Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
DCM Advisors sold 795 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $472K.
DCM Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 4 quarters.
DCM Advisors's Regeneron Pharmaceuticals position peaked at $472K in Q2 2022.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on DCM Advisors's 13F filing for Q3 2022, filed 11 Sep 2023.